Precision Biosciences (DTIL) Times Interest Earned (2018 - 2026)
Precision Biosciences (DTIL) posted quarterly Times Interest Earned of -$18.19 for Q1 2026, up 60.19% year-over-year from -$11.35 in Q1 2025, and down 140.86% quarter-over-quarter from $44.51 in Q4 2025.
Precision Biosciences (DTIL) Times Interest Earned (2018 - 2026) Analysis & Trends
Precision Biosciences (DTIL) has reported Times Interest Earned for 9 consecutive years, with -$18.19 the latest figure, recorded in Q1 2026.
- In Q1 2026, Times Interest Earned rose 60.19% year-over-year to -$18.19; the TTM figure through Mar 2026 stood at -$21.9 (up 2.89% YoY), while the FY2025 annual figure was -$0.36, down 87.79% from the prior year.
- Times Interest Earned eased to -$18.19 in Q1 2026 per DTIL's latest filing, from $44.51 in the prior quarter.
- Across five years, Times Interest Earned topped out at $44.51 in Q4 2025 and bottomed at -$47.6 in Q4 2024.
- Historically, Times Interest Earned has averaged -$13.39 across 5 years, with a median of -$15.54 in 2025.
- Annual changes were most pronounced in 2022 — Times Interest Earned sank 2453.64% — and 2024, when it jumped 573.76%.
- Precision Biosciences' Times Interest Earned stood at -$17.57 in 2022, then sank by 125.93% to -$39.71 in 2023, then slipped by 19.87% to -$47.6 in 2024, then surged by 193.52% to $44.51 in 2025, then sank by 140.86% to -$18.19 in 2026.
- Business Quant data shows DTIL's Times Interest Earned at -$18.19 in Q1 2026, $44.51 in Q4 2025, and -$2.58 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 2.82 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 76.86 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.08 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.42 |
| 10 | Precision Biosciences | 228.31 Mn | 140.77 Mn | - | -63.87 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.94 |
| Mar 31, 2026 | -18.19 |
| Dec 31, 2025 | 44.51 |
| Sep 30, 2025 | -2.58 |
| Jun 30, 2025 | -15.54 |
| Mar 31, 2025 | -45.69 |
| Dec 31, 2024 | -47.60 |
| Sep 30, 2024 | -2.14 |
| Jun 30, 2024 | 2.32 |
| Mar 31, 2024 | -7.29 |
| Dec 31, 2023 | -39.71 |
| Sep 30, 2023 | -18.10 |
| Jun 30, 2023 | -0.49 |
| Mar 31, 2023 | -23.35 |
| Dec 31, 2022 | -17.57 |
| Sep 30, 2022 | -27.74 |
| Jun 30, 2022 | -4.55 |
| Mar 31, 2022 | -3.87 |
| Dec 31, 2021 | -579.70 |
| Sep 30, 2021 | -1.09 |